CDMOs Invested $1 Billion in Global Manufacturing
Pharmaceutical manufacturers are integrating packaging into development to accelerate production cycles.
Updated on Oct. 2, 2026 in Consumer Goods
Live Poll
Do you trust companies that bundle multiple services into one provider to deliver better overall outcomes?
Contract development and manufacturing organizations (CDMOs) have launched $1 billion in global infrastructure investments to consolidate drug formulation and packaging workflows. These efforts aim to shorten time-to-market for pharmaceutical companies by aligning packaging requirements earlier in the development lifecycle.
Why it matters
By merging development and packaging, companies are attempting to reduce operational complexity and increase accountability within their supply chains. This shift enables firms to navigate regulatory and human factors requirements more effectively during the initial phases of production.
PCI Pharma Services has committed over $1 billion to infrastructure growth, including a $100 million expansion at its San Diego site. Meanwhile, Vetter is constructing a 160,000-square-foot facility in Des Plaines, IL, to bolster its global manufacturing footprint.
The players
PCI Pharma Services
A global provider of pharmaceutical outsourcing services specializing in drug development, clinical trials, and commercial packaging.
Vetter
An international manufacturer specializing in the aseptic filling and packaging of clinical and commercial injectable drugs.
Thermo Fisher Scientific
A multinational life sciences company that provides analytical instruments, laboratory equipment, and contract manufacturing services.
Allure Beauty Concepts
A contract manufacturer that recently upgraded its Scottsdale facility to meet FDA and cGMP compliance standards.
Sanofi
A global healthcare firm that divested its Ridgefield, NJ, sterile manufacturing site to focus its internal manufacturing operations.
The details
CDMOs are moving toward hybrid models where packaging expertise is baked into the drug formulation process rather than managed as a downstream task. Companies like Thermo Fisher Scientific have secured sterile manufacturing capacity, such as the Ridgefield, NJ, site acquired from Sanofi in 2025, to provide end-to-end services. Concurrently, specialized firms like Allure Beauty Concepts have moved to ensure compliance by converting facilities into FDA-registered, cGMP-compliant sites.
Timeline
Thermo Fisher acquired the Ridgefield, NJ, site in 2025.
The San Diego isolator line is expected to be operational in 2028.
The Des Plaines, IL, clinical facility is scheduled for 2029.
Market Landscape
This wave of capital expenditure marks a significant acceleration of the established industry trend toward vertical integration. By owning both the clinical manufacturing and the specialized packaging, CDMOs are moving to capture more margin while reducing handover risks for pharmaceutical clients.
Operators in the pharmaceutical supply chain should audit their current packaging-to-manufacturing handoffs to identify potential latency in their own production timelines. Businesses should evaluate if their current partners offer integrated compliance and packaging support to avoid the costs of siloed workflows.
The takeaway
The move toward integrated manufacturing and packaging is setting a new performance standard for speed and compliance in drug production. Operators should review their existing contracts to ensure their manufacturing partners are equipped to handle end-to-end packaging requirements.
Further reading
For more on shifts in manufacturing capacity, explore the Consumer Goods section.
Source note: This article includes information reported by PlasticsToday.
Live Poll
Do you trust companies that bundle multiple services into one provider to deliver better overall outcomes?
